FDA Cites Akorn’s Exhibit Banner At ASHP Clinical Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
Booth promotion for Nembutal fails to disclose any risk information, Office of Prescription Drug Promotion says in the fifth letter issued this year.